arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2013-19-5-458-471arthyper-94Research ArticleОБЗОРREVIEWКОГДА НАЗНАЧАТЬ ВАЛСАРТАН? ПРИМЕНЕНИЕ БЛОКАТОРА РЕЦЕПТОРОВ АНГИОТЕНЗИНА ВАЛСАРТАНА В ФАРМАКОТЕРАПИИ СЕРДЕЧНО-СОСУДИСТЫХ ЗАБОЛЕВАНИЙVALSARTAN IN PHARMACOTHERAPY OF CARDIOVASCULAR DISEASESМаксимовМ. Л.MaksimovM. L.

Доктор медицинских наук, профессор кафедры клинической фармакологии и пропедевтики внутренних болезней лечебного факультета, профессор кафедры фармакологии фармацевтического факультета Первого МГМУ им. И.М. Сеченова.

Контактная информация: ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, ул. Трубецкая, д. 8, стр. 2, Москва, Россия, 119991. E-mail: maksim_maksimov@mail.ru (Максимов Максим Леонидович).

Corresponding author: I.M. Sechenov First Moscow State Medical University, 8–2 Trubetskaya st., Moscow, Russia, 119991. E-mail: maksim_maksimov@mail.ru (Maxim L. Maximov, MD, PhD, Professor at the Department of Clinical Pharmacology and Propedeutics of Internal Diseases at Medical Faculty, Professor at the Department of Pharmacology at the Pharmaceutic Faculty at  I.M. Sechenov First Moscow State Medical University).

maksim_maksimov@mail.ruЕрмолаеваА. С.ErmolaevaA. S.

Аспирант кафедры клинической фармакологии и пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. Сеченова

maksim_maksimov@mail.ruДраловаО. В.DralovaO. V.

Кандидат медицинских наук, доцент кафедры клинической фармакологии и пропедевтики внутренних болезней лечебного факультета Первого МГМУ им. И.М. Сеченова

maksim_maksimov@mail.ruПервый Московский государственный медицинский университет им. И.М. Сеченова, МоскваРоссияI.M. Sechenov First Moscow State Medical University, MoscowRussian Federation201328102013195458471Copyright © Максимов М.Л., Ермолаева А.С., Дралова О.В., 20132013Максимов М.Л., Ермолаева А.С., Дралова О.В.Maksimov M.L., Ermolaeva A.S., Dralova O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/94

Блокаторы рецепторов ангиотензина — одна из наиболее актуальных фармакологических групп в лечении большинства сердечно-сосудистых патологий. В обзорной статье приведены результаты собственных клинических исследований воспроизведенного препарата валсартана — Вальсакора. Валсартан — препарат, сочетающий высокую антигипертензивную эффективность, органопротекцию с хорошей переносимостью, отсутствием риска значимых лекарственных взаимодействий и простотой использования. Отмечен положительный метаболический профиль препарата, что позволяет рассматривать валсартан как средство выбора при сочетании артериальной гипертензии с метаболическим синдромом и сахарным диабетом 2-го типа, длительная терапия снижает риск развития новых случаев сахарного диабета. Лечение валсартаном эффективно при первичной и вторичной профилактике фибрилляции предсердий, хронической сердечной недостаточности и хронической почечной недостаточности. 

Angiotensin receptor blockers represent a relevant group of cardiovascular drugs. The results of clinical trials of a generic Valsartan (Valsakor) are reviewed in the paper. Valsartan combines high antihypertensive and organoprotective effects with the low risk of signiicant drug interactions. Due to the favorable metabolic proile valsartan is the drug of choice in hypertension, metabolic syndrome and type 2 diabetes mellitus, and the long-term therapy is associated with the reduction of the risk of new-onset diabetes. Valsartan is effective in primary and secondary prevention of atrial ibrillation, congestive heart failure and chronic renal failure.

валсартанренин-ангиотензин-альдостероновая системаблокаторы рецепторов ангиотензинаартериальная гипертензиясердечно-сосудистые заболеваниясартанысердечная недостаточностьvalsartanthe renin-angiotensin-aldosterone systemangiotensin receptor blockershypertensioncardiovascular diseaseheart failureReferencesBissessor N., White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction // Vasc. Health Risk Manag. — 2007. — Vol. 3, № 4. — P. 425–430.Bissessor N., White H. Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction // Vasc. Health Risk Manag. — 2007. — Vol. 3, № 4. — P. 425–430.Ortlepp J.P., Vosberg H.P., Reith S. et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of ive polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene // Heart. — 2002. — Vol. 87, № 3. — P. 270–275.Ortlepp J.P., Vosberg H.P., Reith S. et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of ive polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene // Heart. — 2002. — Vol. 87, № 3. — P. 270–275.Griendling K.K., Murphy T.J., Alexander R.W. Molecular biology of the renin-angiotensin system // Circulation. — 1993. — Vol. 87, № 6. — P. 1816–1828.Griendling K.K., Murphy T.J., Alexander R.W. Molecular biology of the renin-angiotensin system // Circulation. — 1993. — Vol. 87, № 6. — P. 1816–1828.Unger T. Blood pressure lowering and renin-angiotensin system blockade // J. Hypertens. — 2003. — Vol. 21, Suppl. 6. — P. S3–S7.Unger T. Blood pressure lowering and renin-angiotensin system blockade // J. Hypertens. — 2003. — Vol. 21, Suppl. 6. — P. S3–S7.Erdos E.G. Angiotensin I converting enzyme and the changes in our concepts through the years // Hypertension. — 1990. — Vol. 16, № 4. — P. 363–370.Erdos E.G. Angiotensin I converting enzyme and the changes in our concepts through the years // Hypertension. — 1990. — Vol. 16, № 4. — P. 363–370.Perazella M.A., Setaro J.F. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders // J. Nucl. Cardiol. — 2003. — Vol. 10, № 2. — P. 184–194.Perazella M.A., Setaro J.F. Renin-angiotensin-aldosterone system: fundamental aspects and clinical implications in renal and cardiovascular disorders // J. Nucl. Cardiol. — 2003. — Vol. 10, № 2. — P. 184–194.Kobori H., Nangaku M., Navar L.G., Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the patho-biology of hypertension and kidney disease // Pharmacol. Rev. — 2007. — Vol. 59, № 3. — P. 251–287.Kobori H., Nangaku M., Navar L.G., Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the patho-biology of hypertension and kidney disease // Pharmacol. Rev. — 2007. — Vol. 59, № 3. — P. 251–287.Исследование эффективности и безопасности валсартана (Вальсакора) в терапии пациентов с мягкой и умеренной гипертензией. Собственные данные КРКА, Новое место, 2009. / Eficacy and safety of valsartan (Valsakor) therapy in patients with mild to moderate hypertension. KRKA's own data, new place, in 2009 [Russian].Исследование эффективности и безопасности валсартана (Вальсакора) в терапии пациентов с мягкой и умеренной гипертензией. Собственные данные КРКА, Новое место, 2009. / Eficacy and safety of valsartan (Valsakor) therapy in patients with mild to moderate hypertension. KRKA's own data, new place, in 2009 [Russian].Остроумова О.Д., Гусева Т.Ф., Шорикова Е.Г. Применение препарата Вальсакор при артериальной гипертонии: результаты словенского многоцентрового исследования // Рус. мед. журн. — 2010. — Т. 18, № 2. — [Электронный ресурс]. — URL: http://www.rmj.ru/articles_7092.htm. / Ostroumova O.D., Guseva T.F., Shorikova E.G. Use of the drug Valsakor in hypertension: results of a multicenter study of Slovene // Russian Medical Journal [Rossiyskiy Meditsinskiy Zhurnal]. — 2010. — Vol. 18, № 2. — [Electronic resource]. — URL: http://www.rmj.ru/articles_7092.htm [Russian].Остроумова О.Д., Гусева Т.Ф., Шорикова Е.Г. Применение препарата Вальсакор при артериальной гипертонии: результаты словенского многоцентрового исследования // Рус. мед. журн. — 2010. — Т. 18, № 2. — [Электронный ресурс]. — URL: http://www.rmj.ru/articles_7092.htm. / Ostroumova O.D., Guseva T.F., Shorikova E.G. Use of the drug Valsakor in hypertension: results of a multicenter study of Slovene // Russian Medical Journal [Rossiyskiy Meditsinskiy Zhurnal]. — 2010. — Vol. 18, № 2. — [Electronic resource]. — URL: http://www.rmj.ru/articles_7092.htm [Russian].Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors // Pharmacol. Rev. — 2000. — Vol. 52, № 3. — P. 415–472.Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology. XXIII. The angiotensin II receptors // Pharmacol. Rev. — 2000. — Vol. 52, № 3. — P. 415–472.Goodfriend Т.L. Angiotensins: actions and receptors / In Hypertension. Ed. by S. Oparil, M. Weber. — 2000. — P. 11–13.Goodfriend Т.L. Angiotensins: actions and receptors / In Hypertension. Ed. by S. Oparil, M. Weber. — 2000. — P. 11–13.Goodfriend T.L., Elliott M.E., Catt K.J. Angiotensin receptors and their antagonists // N. Engl. J. Med. — 1996. — Vol. 334. — P. 1649–1654.Goodfriend T.L., Elliott M.E., Catt K.J. Angiotensin receptors and their antagonists // N. Engl. J. Med. — 1996. — Vol. 334. — P. 1649–1654.Клиническая фармакология / Учеб. под ред. В.Г. Кукеса. — 4е изд. — М. : ГЭОТАР-Медиа, 2008. — 1056 с. / Clinical pharmacology / Textbook ed. by V.G. Kukes. — 4th ed. — Moscow: GEOTAR Media, 2008. – 1056 p. [Russian].Клиническая фармакология / Учеб. под ред. В.Г. Кукеса. — 4е изд. — М. : ГЭОТАР-Медиа, 2008. — 1056 с. / Clinical pharmacology / Textbook ed. by V.G. Kukes. — 4th ed. — Moscow: GEOTAR Media, 2008. – 1056 p. [Russian].Brugts J.J., den Uil C.A., Danser A.H.J., Boersma E. The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease // Cardiology. — 2009. — Vol. 112, № 4. — P. 303–312.Brugts J.J., den Uil C.A., Danser A.H.J., Boersma E. The renin-angiotensin-aldosterone system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease // Cardiology. — 2009. — Vol. 112, № 4. — P. 303–312.Weber M.A. Angiotensin II receptor blockers / In Hypertension. Ed. by S. Oparil, M. Weber. — 2000. — P. 377–378.Weber M.A. Angiotensin II receptor blockers / In Hypertension. Ed. by S. Oparil, M. Weber. — 2000. — P. 377–378.Кобалава Ж.Д., Гудков К.М. Эволюция представлений о стресс-индуцированной артериальной гипертонии и применение антагонистов рецепторов ангиотензина II // Кардиоваск. тер. профилактика. — 2002. — Т. 1. — С. 4–15. / Kobalava Zh.D., Gudkov K.M. The evolution of ideas about the stress-induced hypertension and the use of angiotensin receptor antagonists II // Cardiovascular Therapy and Prevention [Kardiovaskulyarnaya Terapiya i Proilaktika]. — 2002. — Vol. 1. — P. 4–15 [Russian].Кобалава Ж.Д., Гудков К.М. Эволюция представлений о стресс-индуцированной артериальной гипертонии и применение антагонистов рецепторов ангиотензина II // Кардиоваск. тер. профилактика. — 2002. — Т. 1. — С. 4–15. / Kobalava Zh.D., Gudkov K.M. The evolution of ideas about the stress-induced hypertension and the use of angiotensin receptor antagonists II // Cardiovascular Therapy and Prevention [Kardiovaskulyarnaya Terapiya i Proilaktika]. — 2002. — Vol. 1. — P. 4–15 [Russian].Weir M.R. Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers // Curr. Hypertens. Rep. — 2002. — Vol. 4, № 5. — P. 333–335.Weir M.R. Opportunities for cardiovascular risk reduction with angiotensin II receptor blockers // Curr. Hypertens. Rep. — 2002. — Vol. 4, № 5. — P. 333–335.Burnier M., Maillard M. The comparative pharmacology of angiotensin II receptor antagonists // Blood Press. — 2001. — Vol. 10, Suppl. 1. — P. 6–11.Burnier M., Maillard M. The comparative pharmacology of angiotensin II receptor antagonists // Blood Press. — 2001. — Vol. 10, Suppl. 1. — P. 6–11.Waldmeier F., Flesch G., Muller P. et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose // Xenobiotica. — 1997. — Vol. 27, № 1. — P. 59–71.Waldmeier F., Flesch G., Muller P. et al. Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose // Xenobiotica. — 1997. — Vol. 27, № 1. — P. 59–71.Моисеев С.В. Валсартан: от реалий клинической практики к новым возможностям // Клинич. фармакол. фармакотер. — 2009. — T. 18, № 3. — С. 2–7. / Moiseev S.V. Valsartan: from clinical practice to new opportunities // Clinical Pharmacology and Pharmacotherapy [Klinicheskaya Farmakologiya i Farmakoterapiya]. — 2009. — Vol. 18, № 3. — P. 2–7 [Russian].Моисеев С.В. Валсартан: от реалий клинической практики к новым возможностям // Клинич. фармакол. фармакотер. — 2009. — T. 18, № 3. — С. 2–7. / Moiseev S.V. Valsartan: from clinical practice to new opportunities // Clinical Pharmacology and Pharmacotherapy [Klinicheskaya Farmakologiya i Farmakoterapiya]. — 2009. — Vol. 18, № 3. — P. 2–7 [Russian].Lacourciere Y., Poirier L., Hebert D. et al. Antihypertensive eficacy and tolerability of two ixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, double-blind, parallel-group trial // Clin. Ther. — 2005. — Vol. 27, № 7. — P. 1013–1021.Lacourciere Y., Poirier L., Hebert D. et al. Antihypertensive eficacy and tolerability of two ixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, double-blind, parallel-group trial // Clin. Ther. — 2005. — Vol. 27, № 7. — P. 1013–1021.Malacco E., Vari N., Capuano V. et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study // Clin. Ther. — 2003. — Vol. 25, № 11. — P. 2765–2780.Malacco E., Vari N., Capuano V. et al. A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study // Clin. Ther. — 2003. — Vol. 25, № 11. — P. 2765–2780.Свиряев Ю.В., Звартау Н.Э. Антагонисты рецепторов к ангиотензину II 1 типа при сердечно-сосудистых заболеваниях: место валсартана // Артериальная гипертензия. — 2011. — Т. 17, № 4. — С. 325–332. / Sviryaev Yu.V., Zvartau N.E. Antagonists of angiotensin II receptor type 1 in cardiovascular diseases: the place of valsartan // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2011. — Vol. 17, № 4. — P. 325–332 [Russian].Свиряев Ю.В., Звартау Н.Э. Антагонисты рецепторов к ангиотензину II 1 типа при сердечно-сосудистых заболеваниях: место валсартана // Артериальная гипертензия. — 2011. — Т. 17, № 4. — С. 325–332. / Sviryaev Yu.V., Zvartau N.E. Antagonists of angiotensin II receptor type 1 in cardiovascular diseases: the place of valsartan // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2011. — Vol. 17, № 4. — P. 325–332 [Russian].Чудновская Е.А., Струтынский А.В. Применение блокаторов АТ1-рецепторов ангиотензина в патогенетической терапии артериальной гипертензии // Рус. мед. журн. — 2004. — Т. 12. — [Электронный ресурс]. — URL: http://www.medlinks.ru/article.php?sid=20779 / Chudnovskaya E.A., Strutynskiy A.V. AT1-receptor blockers in the pathogenetic therapy of hypertension // Russian Medical Journal [Russkiy Meditsinskiy Zhurnal]. — 2004. — Vol. 12. — [Electronic resource]. — URL: http://www.medlinks.ru/article.php?sid=20779 [Russian].Чудновская Е.А., Струтынский А.В. Применение блокаторов АТ1-рецепторов ангиотензина в патогенетической терапии артериальной гипертензии // Рус. мед. журн. — 2004. — Т. 12. — [Электронный ресурс]. — URL: http://www.medlinks.ru/article.php?sid=20779 / Chudnovskaya E.A., Strutynskiy A.V. AT1-receptor blockers in the pathogenetic therapy of hypertension // Russian Medical Journal [Russkiy Meditsinskiy Zhurnal]. — 2004. — Vol. 12. — [Electronic resource]. — URL: http://www.medlinks.ru/article.php?sid=20779 [Russian].Abts M., Claus V., Lataster M. Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: The MACHT Observational Study // Blood Press. — 2006. — Vol. 15, suppl. 1. — P. 27–32.Abts M., Claus V., Lataster M. Blood pressure control with valsartan and hydrochlorothiazide in clinical practice: The MACHT Observational Study // Blood Press. — 2006. — Vol. 15, suppl. 1. — P. 27–32.Минушкина Л.О., Затейщиков Д.А. Место валсартана в лечении артериальной гипертонии // Кардиология. — 2004. — № 14. — С. 59–65. / Minushkina L.O., Zateyschikov D.A. Valsartan role in hypertension treatment // Cardiology [Kardiologiia]. — 2004. — № 14. — P. 59–65 [Russian].Минушкина Л.О., Затейщиков Д.А. Место валсартана в лечении артериальной гипертонии // Кардиология. — 2004. — № 14. — С. 59–65. / Minushkina L.O., Zateyschikov D.A. Valsartan role in hypertension treatment // Cardiology [Kardiologiia]. — 2004. — № 14. — P. 59–65 [Russian].Hermida R.C., Calvo C., Ayala D.E. et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects // Hypertension. — 2003. — Vol. 42, № 3. — P. 283–290.Hermida R.C., Calvo C., Ayala D.E. et al. Administration time-dependent effects of valsartan on ambulatory blood pressure in hypertensive subjects // Hypertension. — 2003. — Vol. 42, № 3. — P. 283–290.Calvo C., Hermida R.C., Ayala D.E., Ruilope L.M. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension // J. Hypertens. — 2004. — Vol. 22, № 4. — P. 837–846.Calvo C., Hermida R.C., Ayala D.E., Ruilope L.M. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension // J. Hypertens. — 2004. — Vol. 22, № 4. — P. 837–846.Fogari R., Zoppi A., Mugellini A. et al. Comparative eficacy of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring // Curr. Therap. Res. — 1999. — Vol. 60. — P. 195–206.Fogari R., Zoppi A., Mugellini A. et al. Comparative eficacy of losartan and valsartan in mild-to-moderate hypertension: results of 24-hour ambulatory blood pressure monitoring // Curr. Therap. Res. — 1999. — Vol. 60. — P. 195–206.Fogari R., Mugellini A., Zoppi A. et al. A double-blind, crossover study of the antihypertensive eficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system // Curr. Therap. Res. — 2000. — Vol. 61. — P. 669–679.Fogari R., Mugellini A., Zoppi A. et al. A double-blind, crossover study of the antihypertensive eficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system // Curr. Therap. Res. — 2000. — Vol. 61. — P. 669–679.Fogari R., Mugellini A., Zoppi A. et al. Eficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring // Curr. Therap. Res. — 2002. — Vol. 63. — P. 1–14.Fogari R., Mugellini A., Zoppi A. et al. Eficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: a double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring // Curr. Therap. Res. — 2002. — Vol. 63. — P. 1–14.Julius S., Bach D., Kjeldsen S. et al. Predictors of one year blood pressure control and treatment resistance in the VALUE trial // Am. J. Hypertens. — 2002. — Vol. 15. — P. 111A.Julius S., Bach D., Kjeldsen S. et al. Predictors of one year blood pressure control and treatment resistance in the VALUE trial // Am. J. Hypertens. — 2002. — Vol. 15. — P. 111A.Julius S., Kjeldsen S., Brunner H. et al. VALUE trial: long term blood pressure trends in 13449 patients with hypertension and high cardiovascular risk // Am. J. Hypertens. — 2003. — Vol. 16, № 7. — P. 544–548.Julius S., Kjeldsen S., Brunner H. et al. VALUE trial: long term blood pressure trends in 13449 patients with hypertension and high cardiovascular risk // Am. J. Hypertens. — 2003. — Vol. 16, № 7. — P. 544–548.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial // Lancet. — 2004. — Vol. 363, № 9426. — P. 2022–2031.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial // Lancet. — 2004. — Vol. 363, № 9426. — P. 2022–2031.Csaika C., Buclin T., Brunner H.R., Biollaz J. Pharmacokinetic-pharmacodynamic proile of angiotensin II receptor antagonists // Clin. Pharmacokinet. — 1997. — Vol. 32, № 1. — P. 1–29.Csaika C., Buclin T., Brunner H.R., Biollaz J. Pharmacokinetic-pharmacodynamic proile of angiotensin II receptor antagonists // Clin. Pharmacokinet. — 1997. — Vol. 32, № 1. — P. 1–29.Stokes J., Kannel W.B., Wolf P.A. et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham study -30 years of follow-up // Hypertension. — 1989. — Vol. 13, suppl. 5. — P. 133–135.Stokes J., Kannel W.B., Wolf P.A. et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham study -30 years of follow-up // Hypertension. — 1989. — Vol. 13, suppl. 5. — P. 133–135.Foote E.F., Halstenson C.E. New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors // Ann. Pharmacother. — 1993. — Vol. 27, № 12. — P. 1495–1503.Foote E.F., Halstenson C.E. New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors // Ann. Pharmacother. — 1993. — Vol. 27, № 12. — P. 1495–1503.Neutel J., Weber M., Pool J. et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours // Clin. Ther. — 1997. — Vol. 19, № 3. — P. 447–458.Neutel J., Weber M., Pool J. et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours // Clin. Ther. — 1997. — Vol. 19, № 3. — P. 447–458.Oparil S., Dyke S., Harris F. et al. The efficacy and safety of valsartan compared with placebo in the treatment of essential hypertension // Clin. Ther. — 1996. — Vol. 18, № 5. — P. 797–810.Oparil S., Dyke S., Harris F. et al. The efficacy and safety of valsartan compared with placebo in the treatment of essential hypertension // Clin. Ther. — 1996. — Vol. 18, № 5. — P. 797–810.Hall J., Marbury T., Gray J. et al. Long term safety, tolerability and eficacy of valsartan: results from one and two years trials // J. Clin. Res. — 1998. — Vol. 1. — P. 147–159.Hall J., Marbury T., Gray J. et al. Long term safety, tolerability and eficacy of valsartan: results from one and two years trials // J. Clin. Res. — 1998. — Vol. 1. — P. 147–159.Holwerda N.J., Fogari R., Angeli P. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril // J. Hypertens. — 1996. — Vol. 14, № 9. — P. 1147–1151.Holwerda N.J., Fogari R., Angeli P. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril // J. Hypertens. — 1996. — Vol. 14, № 9. — P. 1147–1151.Свищенко Е.П., Матова Е.А., Мищенко Л.А. Диастолическая дисфункция ЛЖ у больных гипертонической болезнью: возможности коррекции с помощью валсартана // Артериальная гипертензия. — 2012. — Т. 22, № 2. — С. 36–43. / Svishchenko E.P., Matova E.A., Mishchenko L.A. Diastolic dysfunction in hypertensive patients: possible correction using valsartan // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2012. — Vol. 22, № 2. — Р. 36–43 [Russian].Свищенко Е.П., Матова Е.А., Мищенко Л.А. Диастолическая дисфункция ЛЖ у больных гипертонической болезнью: возможности коррекции с помощью валсартана // Артериальная гипертензия. — 2012. — Т. 22, № 2. — С. 36–43. / Svishchenko E.P., Matova E.A., Mishchenko L.A. Diastolic dysfunction in hypertensive patients: possible correction using valsartan // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2012. — Vol. 22, № 2. — Р. 36–43 [Russian].Ruilope L.M., Malacco E., Khder Y., Kandra A., Bonner G., Heintz D. Eficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascularrisk factors: the VAST study // Clin. Ther. — 2005. — Vol. 27, № 5. — P. 578–587.Ruilope L.M., Malacco E., Khder Y., Kandra A., Bonner G., Heintz D. Eficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascularrisk factors: the VAST study // Clin. Ther. — 2005. — Vol. 27, № 5. — P. 578–587.Griin A., Francillon A., Bodin F. et al. A comparison of the eficacy and tolerability of a new angiotensin II antagonist, valsartan, with enalapril in patients with mild-to-moderate essential hypertension // Eur. Heart J. — 1995. — Vol. 16, suppl. — P. 61.Griin A., Francillon A., Bodin F. et al. A comparison of the eficacy and tolerability of a new angiotensin II antagonist, valsartan, with enalapril in patients with mild-to-moderate essential hypertension // Eur. Heart J. — 1995. — Vol. 16, suppl. — P. 61.Black H.R., Graff A., Shute D. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. Eficacy, tolerability and safety compared to an angiotensin converting enzyme inhibitor lisinopril (protocol 50). Novartis, 1997.Black H.R., Graff A., Shute D. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension. Eficacy, tolerability and safety compared to an angiotensin converting enzyme inhibitor lisinopril (protocol 50). Novartis, 1997.Valsartan: long term eficacy and tolerability compared to lisinopril in elderly patients with essential hypertension (protocol 28). Novartis, 1996.Valsartan: long term eficacy and tolerability compared to lisinopril in elderly patients with essential hypertension (protocol 28). Novartis, 1996.Ridker P.M., Danielson E, Rifai N., Glynn R.J. Valsartan, blood pressure reduction, and c-reactive protein primary report of the Val-MARC Trial // Hypertension. — 2006. — Vol. 48, № 1. — P. 73–79.Ridker P.M., Danielson E, Rifai N., Glynn R.J. Valsartan, blood pressure reduction, and c-reactive protein primary report of the Val-MARC Trial // Hypertension. — 2006. — Vol. 48, № 1. — P. 73–79.Benz J., Black H., Graff A., Reed A., Fitzsimmons S., Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy // J. Hum. Hypertens. — 1998. — Vol. 12, № 12. — P. 861–866.Benz J., Black H., Graff A., Reed A., Fitzsimmons S., Shi Y. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy // J. Hum. Hypertens. — 1998. — Vol. 12, № 12. — P. 861–866.Ронжина О.А., Фомина Н.В. Опыт лечения артериальной гипертензии препаратом Вальсакор у спортсменов-тяжелоатлетов // Лечебная физкультура и спортивная медицина. — 2013. — Т. 114, № 6. — С. 15–21. / Ronzhina O.A., Fomina N.V. Experience in treating hypertension by Valsakor in weightlifting athletes // Physiotherapy and Sports Medicine [Lechebnaya Fizkultura i Sportivnaya Meditsina]. — 2013. — Vol. 114, № 6. — Р. 15–21 [Russian].Ронжина О.А., Фомина Н.В. Опыт лечения артериальной гипертензии препаратом Вальсакор у спортсменов-тяжелоатлетов // Лечебная физкультура и спортивная медицина. — 2013. — Т. 114, № 6. — С. 15–21. / Ronzhina O.A., Fomina N.V. Experience in treating hypertension by Valsakor in weightlifting athletes // Physiotherapy and Sports Medicine [Lechebnaya Fizkultura i Sportivnaya Meditsina]. — 2013. — Vol. 114, № 6. — Р. 15–21 [Russian].Kjeldsen S.E., Julius S., Brunner H. et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The valsartan antihypertensive long-term use evaluation // Blood Press. — 2001. — Vol. 10, № 2. — P. 83–91.Kjeldsen S.E., Julius S., Brunner H. et al. Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The valsartan antihypertensive long-term use evaluation // Blood Press. — 2001. — Vol. 10, № 2. — P. 83–91.Weycker D., Edelsberg J., Vincze G. et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine // J. Hum. Hypertens. — 2007. — Vol. 21, № 5. — P. 374–380.Weycker D., Edelsberg J., Vincze G. et al. Risk of diabetes in a real-world setting among patients initiating antihypertensive therapy with valsartan or amlodipine // J. Hum. Hypertens. — 2007. — Vol. 21, № 5. — P. 374–380.Weycker D., Falvey H., Edelsberg J., Oster J. Risk of diabetes in hypertensive patients receiving valsartan versus losartan // J. Clin. Hypertens. — 2007. — Vol. 9, suppl. A. — P. 448.Weycker D., Falvey H., Edelsberg J., Oster J. Risk of diabetes in hypertensive patients receiving valsartan versus losartan // J. Clin. Hypertens. — 2007. — Vol. 9, suppl. A. — P. 448.Viberti G., Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect // Circulation. — 2002. — Vol. 106, № 6. — Р. 672–678.Viberti G., Wheeldon N.M. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect // Circulation. — 2002. — Vol. 106, № 6. — Р. 672–678.Uzu T., Sawaguchi M., Maegawa H., Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART) // Diabetes Care. — 2007. — Vol. 30, № 6. — P. 1581–1583.Uzu T., Sawaguchi M., Maegawa H., Kashiwagi A. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART) // Diabetes Care. — 2007. — Vol. 30, № 6. — P. 1581–1583.Dahlof B. Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond // J. Renin Angiotensin Aldosterone Syst. — 2000. — Vol. 1, 2 Suppl. — P. S14–S16.Dahlof B. Valsartan and the renin-angiotensin-aldosterone system: blood pressure control and beyond // J. Renin Angiotensin Aldosterone Syst. — 2000. — Vol. 1, 2 Suppl. — P. S14–S16.Bedigian M.P. Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) theapy // J. Renin Angiotensin Aldosterone Syst. — 2000. — Vol. 1, 2 Suppl. — P. S25–S28.Bedigian M.P. Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) theapy // J. Renin Angiotensin Aldosterone Syst. — 2000. — Vol. 1, 2 Suppl. — P. S25–S28.Hollenberg N.K., Parving H.H., Viberti G. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1921–1926.Hollenberg N.K., Parving H.H., Viberti G. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus // J. Hypertens. — 2007. — Vol. 25, № 9. — P. 1921–1926.Smith D.G., Nguyen A.B., Peak C.N., Frech F.H. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria // J. Manag. Care Pharm. — 2004. — Vol. 10,Smith D.G., Nguyen A.B., Peak C.N., Frech F.H. Markov modeling analysis of health and economic outcomes of therapy with valsartan versus amlodipine in patients with type 2 diabetes and microalbuminuria // J. Manag. Care Pharm. — 2004. — Vol. 10,The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events // N. Engl. J. Med. — 2010. — Vol. 362, № 16. — P. 1477–1490.The NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events // N. Engl. J. Med. — 2010. — Vol. 362, № 16. — P. 1477–1490.Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men // Blood Press. Suppl. — 2003. — Vol. 2. — P. 29–34.Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men // Blood Press. Suppl. — 2003. — Vol. 2. — P. 29–34.Fogari R., Preti P., Derosa G. et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men // Eur. J. Clin. Pharma- col. — 2002. — Vol. 58, № 3. — P. 177–180.Fogari R., Preti P., Derosa G. et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men // Eur. J. Clin. Pharma- col. — 2002. — Vol. 58, № 3. — P. 177–180.Вёрткин А.Л., Вилковыский Ф.А., Скотников А.С., Звягинцева Е.И., Скотникова Е.В. Медико-социальное значение сексуальных нарушений и безопасность гипотензивной терапии у мужчин с артериальной гипертонией // Кардиоло- гия. — 2011. — Т. 10. — С. 4–38. / Vertkin A.L., Vilkovyskiy F.A., Skotnikov A.S., Zvyagintseva E.I., Skotnikova E.V. Medical and social implications of sexual disorders and safety of antihypertensive therapy in hypertensive men // Cardiology. — 2011. — Vol. 10. — P. 4–38 [Russian].Вёрткин А.Л., Вилковыский Ф.А., Скотников А.С., Звягинцева Е.И., Скотникова Е.В. Медико-социальное значение сексуальных нарушений и безопасность гипотензивной терапии у мужчин с артериальной гипертонией // Кардиоло- гия. — 2011. — Т. 10. — С. 4–38. / Vertkin A.L., Vilkovyskiy F.A., Skotnikov A.S., Zvyagintseva E.I., Skotnikova E.V. Medical and social implications of sexual disorders and safety of antihypertensive therapy in hypertensive men // Cardiology. — 2011. — Vol. 10. — P. 4–38 [Russian].Remuzzi G., Perico N., Macia M., Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease // Kidney Int. Suppl. — 2005. — Vol. 99. — P. S57–S65.Remuzzi G., Perico N., Macia M., Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease // Kidney Int. Suppl. — 2005. — Vol. 99. — P. S57–S65.Lapinski R., Perico N., Remuzzi A. et al. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney // J. Am. Soc. Nephrol. — 1996. — Vol. 7, № 5. — Р. 653–660.Lapinski R., Perico N., Remuzzi A. et al. Angiotensin II modulates glomerular capillary permselectivity in rat isolated perfused kidney // J. Am. Soc. Nephrol. — 1996. — Vol. 7, № 5. — Р. 653–660.Mezzano S.A., Ruiz-Ortega M., Egido J. Angiotensin II and renal ibrosis // Hypertension. — 2001. — Vol. 38, № 3, Pt. 2. — P. 635–638.Mezzano S.A., Ruiz-Ortega M., Egido J. Angiotensin II and renal ibrosis // Hypertension. — 2001. — Vol. 38, № 3, Pt. 2. — P. 635–638.Швецов М.Ю., Медведева Т.Ю., Козловская Н.Л. и др. Опыт пpименения валсаpтана с целью тоpможения пpогpессиpования почечной недостаточности у больных хpоническим гломеpулонефpитом // Терапевт. арх. — 2001. — № 6. — [Электронный ресурс]. — URL: http://www. medlinks.ru/article.php?sid=3432. / Shvetsov M., Medvedev T.Y., Kozlovskaya N.L. et al. Valsartan as a medium for slowing progres- sion of renal failure in patients with chronic glomerulonephritis // Therapeutic Archive [Terapevticheskiy Arkhiv]. — 2001. — № 6. — [Electronic resource]. — URL: http://www.medlinks.ru/article. php?sid=3432 [Russian].Швецов М.Ю., Медведева Т.Ю., Козловская Н.Л. и др. Опыт пpименения валсаpтана с целью тоpможения пpогpессиpования почечной недостаточности у больных хpоническим гломеpулонефpитом // Терапевт. арх. — 2001. — № 6. — [Электронный ресурс]. — URL: http://www. medlinks.ru/article.php?sid=3432. / Shvetsov M., Medvedev T.Y., Kozlovskaya N.L. et al. Valsartan as a medium for slowing progres- sion of renal failure in patients with chronic glomerulonephritis // Therapeutic Archive [Terapevticheskiy Arkhiv]. — 2001. — № 6. — [Electronic resource]. — URL: http://www.medlinks.ru/article. php?sid=3432 [Russian].Tepel M., van der Giet M., Zidek W. Eficacy and toler- ability of angiotensin II type 1 receptor antagonists in dialysis patients using an69 dialysis membranes // Kidney Blood Press. Res. — 2001. — Vol. 24, № 1. — P. 71–74.Tepel M., van der Giet M., Zidek W. Eficacy and toler- ability of angiotensin II type 1 receptor antagonists in dialysis patients using an69 dialysis membranes // Kidney Blood Press. Res. — 2001. — Vol. 24, № 1. — P. 71–74.Cohn J.N., Tognoni G., for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. — 2001. — Vol. 345, № 23. — Р. 1667–1675.Cohn J.N., Tognoni G., for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure // N. Engl. J. Med. — 2001. — Vol. 345, № 23. — Р. 1667–1675.Maggioni A., Anand I., Gottlieb S. et al. Effects of val- sartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors // J. Am. Coll. Cardiol. — 2002. — Vol. 40, № 8. — P. 1414–1421.Maggioni A., Anand I., Gottlieb S. et al. Effects of val- sartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors // J. Am. Coll. Cardiol. — 2002. — Vol. 40, № 8. — P. 1414–1421.Cohn J., Anand I., Latini R. et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure // Circulation. — 2003. — Vol. 108, № 11. — P. r61-r64.Cohn J., Anand I., Latini R. et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure // Circulation. — 2003. — Vol. 108, № 11. — P. r61-r64.Wong M., Staszewsky L., Latini R. et al. Valsartan beneits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study // J. Am. Coll. Cardiol. — 2002. — Vol. 40, № 5. — P. 970–975.Wong M., Staszewsky L., Latini R. et al. Valsartan beneits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study // J. Am. Coll. Cardiol. — 2002. — Vol. 40, № 5. — P. 970–975.Schmieder R., Hua T. Reduced incidence of new onset atrial ibrillation with angiotensin ii receptor blockade: the VALUE- Trial // J. Hypertens. — 2006. — Vol. 24, suppl. — P. S3.Schmieder R., Hua T. Reduced incidence of new onset atrial ibrillation with angiotensin ii receptor blockade: the VALUE- Trial // J. Hypertens. — 2006. — Vol. 24, suppl. — P. S3.Julius S., Kjeldsen S.E., Brunner H. et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hyperten-№ 1. — P. 26–32.Julius S., Kjeldsen S.E., Brunner H. et al. VALUE trial: long-term blood pressure trends in 13,449 patients with hyperten-№ 1. — P. 26–32.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. — 2004. — Vol. 363, № 9426. — P. 2022–2031.Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial // Lancet. — 2004. — Vol. 363, № 9426. — P. 2022–2031.Julius S., Weber M.A., Kjeldsen S.E. et al. The valsartan antihypertensive long-term use evaluation (value) trial: outcomes in patients receiving monotherapy // Hypertension. — 2006. — Vol. 48, № 3. — P. 385–391.Julius S., Weber M.A., Kjeldsen S.E. et al. The valsartan antihypertensive long-term use evaluation (value) trial: outcomes in patients receiving monotherapy // Hypertension. — 2006. — Vol. 48, № 3. — P. 385–391.Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial ibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) // Am. Heart J. — 2005. — Vol. 149, № 3. — P. 548–557.Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial ibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) // Am. Heart J. — 2005. — Vol. 149, № 3. — P. 548–557.Mutlu H., Scedil I.M. et al. The eficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy // Blood Pressure. — 2002. — Vol. 11, № 1. — P. 53–55.Mutlu H., Scedil I.M. et al. The eficacy of valsartan in essential hypertension and its effects on left ventricular hypertrophy // Blood Pressure. — 2002. — Vol. 11, № 1. — P. 53–55.Thurmann P.A., Kenedi P., Schmidt A. et al. Inluence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension // Circulation. — 1998. — Vol. 98. — P. 2037–2042.Thurmann P.A., Kenedi P., Schmidt A. et al. Inluence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension // Circulation. — 1998. — Vol. 98. — P. 2037–2042.Ивлева А.Я. Новые перспективы в лечении артериальной гипертензии. Антагонист ангиотензина II Валсартана (Диован®) // Терапевт. арх. — 1998. — № 9. — C. 85–88. / Ivleva A.Y. New perspectives in the treatment of hypertension. Angiotensin II antagonist valsartan (Diovan ®) // Therapeutic Archives [Terapevticheskiy Arkhiv]. — 1998. — № 9. — P. 85–88 [Russian].Ивлева А.Я. Новые перспективы в лечении артериальной гипертензии. Антагонист ангиотензина II Валсартана (Диован®) // Терапевт. арх. — 1998. — № 9. — C. 85–88. / Ivleva A.Y. New perspectives in the treatment of hypertension. Angiotensin II antagonist valsartan (Diovan ®) // Therapeutic Archives [Terapevticheskiy Arkhiv]. — 1998. — № 9. — P. 85–88 [Russian].Максимов М.Л., Дербенцева Е.А., Дралова О.В., Стародубцев А.К., Остроумова О.Д. Применение блокатора АТ1-рецепторов ангиотензина II валсартана у пациентов с хронической сердечной недостаточностью // Сердечная недостаточность. — 2010. — Т. 11, № 5 (61). — С. 307–311. / Maksimov M.L, Derbentseva E.A., Dralova O.V., Starodubtsev A.K., Ostroumova O.D. Blocker AT1 angiotensin II receptor valsartan in patients with chronic heart failure // Heart Failure [Serdechnaya Nedostatochnost]. — 2010. — Vol. 11, № 5 (61). — P. 307–311 [Russian].Максимов М.Л., Дербенцева Е.А., Дралова О.В., Стародубцев А.К., Остроумова О.Д. Применение блокатора АТ1-рецепторов ангиотензина II валсартана у пациентов с хронической сердечной недостаточностью // Сердечная недостаточность. — 2010. — Т. 11, № 5 (61). — С. 307–311. / Maksimov M.L, Derbentseva E.A., Dralova O.V., Starodubtsev A.K., Ostroumova O.D. Blocker AT1 angiotensin II receptor valsartan in patients with chronic heart failure // Heart Failure [Serdechnaya Nedostatochnost]. — 2010. — Vol. 11, № 5 (61). — P. 307–311 [Russian].Jackson Т.К., Garrison J.С. The pharmacological basis of therapeutics / Ed. by J.G. Hardmanetal. — 9th ed. — New York, 1996. — P. 733–758.Jackson Т.К., Garrison J.С. The pharmacological basis of therapeutics / Ed. by J.G. Hardmanetal. — 9th ed. — New York, 1996. — P. 733–758.Кобалава Ж.Д. Современные проблемы артериальной гипертонии. Блокаторы рецепторов ангиотензина II: достижения и перспективы. — [Электронный ресурс]. — URL: http://www.cardiosite.ru/articles/article.asp?id=1381 / Kobalava Zh.D. Modern problems of hypertension. Angiotensin receptor II: achievements and prospects. — [Electronic resource]. — URL: http://www.cardiosite.ru/articles/article.asp?id=1381 [Russian].Кобалава Ж.Д. Современные проблемы артериальной гипертонии. Блокаторы рецепторов ангиотензина II: достижения и перспективы. — [Электронный ресурс]. — URL: http://www.cardiosite.ru/articles/article.asp?id=1381 / Kobalava Zh.D. Modern problems of hypertension. Angiotensin receptor II: achievements and prospects. — [Electronic resource]. — URL: http://www.cardiosite.ru/articles/article.asp?id=1381 [Russian].Недогода С.В. Возможности антигипертензивной терапии в предотвращении кардиоренального континуума. — [Электронный ресурс]. — URL: http://medi.ru/doc/271507.htm /Недогода С.В. Возможности антигипертензивной терапии в предотвращении кардиоренального континуума. — [Электронный ресурс]. — URL: http://medi.ru/doc/271507.htm /Nedogoda S.V. Possibility of antihypertensive therapy in the prevention of cardiorenal continuum. — [Electronic resource]. — URL: http://medi.ru/doc/271507.htm [Russian].Nedogoda S.V. Possibility of antihypertensive therapy in the prevention of cardiorenal continuum. — [Electronic resource]. — URL: http://medi.ru/doc/271507.htm [Russian].Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study // Br. Med. J. — 2000. — Vol. 321, № 7274. — P. 1440–1444.Mogensen C.E., Neldam S., Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study // Br. Med. J. — 2000. — Vol. 321, № 7274. — P. 1440–1444.Mann J.F.E., Schmieder R.E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial // Lancet. — 2008. — Vol. 372, № 9638. — P. 547–553.Mann J.F.E., Schmieder R.E., McQueen M. et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial // Lancet. — 2008. — Vol. 372, № 9638. — P. 547–553.Casas J.P., Chua W., Loukogeorgakis S. et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensivedrugs on renal outcomes: systematic review and meta-analysis // Lancet. — 2005. — Vol. 366, № 9502. — P. 2026–2033.Casas J.P., Chua W., Loukogeorgakis S. et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensivedrugs on renal outcomes: systematic review and meta-analysis // Lancet. — 2005. — Vol. 366, № 9502. — P. 2026–2033.Hegner G., Faust G., Freytag F., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treat- ment of essential hypertension: eficacy and safety compared to hydrochlorothiazide // Eur. J. Clin. Pharmacol. — 1997. — Vol. 52, № 3. — P. 173–177.Hegner G., Faust G., Freytag F., Meilenbrock S., Sullivan J., Bodin F. Valsartan, a new angiotensin II antagonist for the treat- ment of essential hypertension: eficacy and safety compared to hydrochlorothiazide // Eur. J. Clin. Pharmacol. — 1997. — Vol. 52, № 3. — P. 173–177.Клинико-фармакологические аспекты взаимодействия лекарственных средств / Под ред. В.Г. Кукеса. — М.: Издательский дом «Русский Врач», 2007. — С. 19–28, 94–95. / Clinical and pharmacological aspects of drug interactions / Ed. by V.G. Kukes. — Moscow: Publishing House «Russian Doctor», 2007. — P. 19–28, 94–95 [Russian].Клинико-фармакологические аспекты взаимодействия лекарственных средств / Под ред. В.Г. Кукеса. — М.: Издательский дом «Русский Врач», 2007. — С. 19–28, 94–95. / Clinical and pharmacological aspects of drug interactions / Ed. by V.G. Kukes. — Moscow: Publishing House «Russian Doctor», 2007. — P. 19–28, 94–95 [Russian].Benz J., Oshrain C., Henry D., Avery C., Chiang Y.T., Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide // J. Clin. Pharmacol. — 1997. — Vol. 37, № 2. — P. 101–107.Benz J., Oshrain C., Henry D., Avery C., Chiang Y.T., Gatlin M. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide // J. Clin. Pharmacol. — 1997. — Vol. 37, № 2. — P. 101–107.Holwerda N.J., Fogari R., Angeli P. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: eficacy and safety compared with placebo and enalapril // J. Hypertens. — 1996. — Vol. 14, № 9. — P. 1147–1151.Holwerda N.J., Fogari R., Angeli P. et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: eficacy and safety compared with placebo and enalapril // J. Hypertens. — 1996. — Vol. 14, № 9. — P. 1147–1151.Bloom B.S. Continuation of initial antihypertensive medi- cation after 1 year of therapy // Clin. Ther. — 1998. — Vol. 20, № 4. — P. 671–681.Bloom B.S. Continuation of initial antihypertensive medi- cation after 1 year of therapy // Clin. Ther. — 1998. — Vol. 20, № 4. — P. 671–681.Вёрткин А.Л, Скотников А.С. Жизнь — театр, а люди в нем — актеры: место антагонистов рецепторов ангиотензина в лечении артериальной гипертензии // Consilium Medicum. — 2011. — Т. 12, № 1. — С. 50–56. / Vertkin A.L., Skotnikov A.S. Life is a theater, and the people are the actors: the place of angiotensin receptor antagonists in the treatment of hypertension // Consilium Medicum. — 2011. — Т. 12, № 1. — С. 50–56 [Russian].Вёрткин А.Л, Скотников А.С. Жизнь — театр, а люди в нем — актеры: место антагонистов рецепторов ангиотензина в лечении артериальной гипертензии // Consilium Medicum. — 2011. — Т. 12, № 1. — С. 50–56. / Vertkin A.L., Skotnikov A.S. Life is a theater, and the people are the actors: the place of angiotensin receptor antagonists in the treatment of hypertension // Consilium Medicum. — 2011. — Т. 12, № 1. — С. 50–56 [Russian].

The authors declare that there are no conflicts of interest present.